Euroscreen S.A.

Euroscreen is a partner of choice for fully integrated drug discovery and GPCR deorphanization programs combining its recognized expertise and its proprietary technology platform.

Most recent partnerships and announcements include:

• Sept 2011: A second deorphanization of new GPCR drug target with Novartis.

• Dec 2010: Drug Development partnership with Ortho-McNeill-Janssen Pharmaceuticals for candidates in the area of metabolic disease.

• Aug 2010: Successful GPCR deorphanization and license payment in our ongoing collaboration with Novartis.

• Dec 2009: Successful completion and milestone payment from our 5-year Cephalon partnership for drug lead development.

Since 1999, Euroscreen has also developed a strong partnering reputation with a large number of customer sales and licensing arrangements in particular with Alcon, Amgen, Amersham-GE, AstraZeneca, Bristol-Myers Squib, Cybio, Epix, Evotec, Genomic Novartis Foundation, GlaxoSmithKline and Merck.